Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 220

1.

848PPROGNOSTIC SIGNIFICANCE OF ACTIVE SURVEILLANCE (AS) IN METASTATIC RENAL CELL CARCINOMA (MRCC).

De Velasco G, Ainsworth N, Holyoake D, Fife K, Matakidou A, Eisen T.

Ann Oncol. 2014 Sep 1;25(suppl_4):iv295. doi: 10.1093/annonc/mdu337.41. No abstract available.

PMID:
28172221
2.

Genetic polymorphisms and sunitinib outcome in metastatic renal-cell carcinoma: A prospective observational study and validation.

Castellano DE, Rodriguez-Antona C, Benitez J, De Velasco G, Villacampa F, de la Rosa F, Andres E, Sepúlveda JM.

J Clin Oncol. 2013 Feb 20;31(6_suppl):403. doi: 10.1200/jco.2013.31.6_suppl.403.

PMID:
28137082
3.

Analysis of molecular profiling of renal cell carcinoma: Identification of a 4-microRNA signature as a prognostic value in patients with stage I-II disease.

Farfán CA, Angelo G, Sepúlveda JM, De Velasco G, Villacampa F, Tejido A, Dominguez M, de la Rosa F, Fresno JA.

J Clin Oncol. 2013 Feb 20;31(6_suppl):395. doi: 10.1200/jco.2013.31.6_suppl.395.

PMID:
28136760
4.

TMEFF2 shedding is regulated by oxidative stress and mediated by ADAMs and transmembrane serine proteases implicated in prostate cancer.

Gaweł-Bęben K, Ali N, Ellis V, Velasco G, Poghosyan Z, Ager A, Knäuper V.

Cell Biol Int. 2017 Aug 1. doi: 10.1002/cbin.10832. [Epub ahead of print]

PMID:
28762604
5.

Pharmacogenomic Markers of Targeted Therapy Toxicity in Patients with Metastatic Renal Cell Carcinoma.

de Velasco G, Gray KP, Hamieh L, Urun Y, Carol HA, Fay AP, Signoretti S, Kwiatkowski DJ, McDermott DF, Freedman M, Pomerantz MM, Choueiri TK.

Eur Urol Focus. 2016 Dec 15;2(6):633-639. doi: 10.1016/j.euf.2016.03.017. Epub 2016 Apr 23.

PMID:
28723497
6.

Erratum: The metabolic co-regulator PGC1α suppresses prostate cancer metastasis.

Torrano V, Valcarcel-Jimenez L, Cortazar AR, Liu X, Urosevic J, Castillo-Martin M, Fernández-Ruiz S, Morciano G, Caro-Maldonado A, Guiu M, Zúñiga-García P, Graupera M, Bellmunt A, Pandya P, Lorente M, Martín-Martín N, Sutherland JD, Sanchez-Mosquera P, Bozal-Basterra L, Zabala-Letona A, Arruabarrena-Aristorena A, Berenguer A, Embade N, Ugalde-Olano A, Lacasa-Viscasillas I, Loizaga-Iriarte A, Unda-Urzaiz M, Schultz N, Aransay AM, Sanz-Moreno V, Barrio R, Velasco G, Pinton P, Cordon-Cardo C, Locasale JW, Gomis RR, Carracedo A.

Nat Cell Biol. 2017 Jun 29;19(7):873. doi: 10.1038/ncb3558.

PMID:
28659639
7.

Angiopoietin-1 enhances neutrophil chemotaxis in vitro and migration in vivo through interaction with CD18 and release of CCL4.

Burnett A, Gomez I, De Leon DD, Ariaans M, Progias P, Kammerer RA, Velasco G, Marron M, Hellewell P, Ridger V.

Sci Rep. 2017 May 24;7(1):2332. doi: 10.1038/s41598-017-02216-y.

8.

A Pan-Cancer Proteogenomic Atlas of PI3K/AKT/mTOR Pathway Alterations.

Zhang Y, Kwok-Shing Ng P, Kucherlapati M, Chen F, Liu Y, Tsang YH, de Velasco G, Jeong KJ, Akbani R, Hadjipanayis A, Pantazi A, Bristow CA, Lee E, Mahadeshwar HS, Tang J, Zhang J, Yang L, Seth S, Lee S, Ren X, Song X, Sun H, Seidman J, Luquette LJ, Xi R, Chin L, Protopopov A, Westbrook TF, Shelley CS, Choueiri TK, Ittmann M, Van Waes C, Weinstein JN, Liang H, Henske EP, Godwin AK, Park PJ, Kucherlapati R, Scott KL, Mills GB, Kwiatkowski DJ, Creighton CJ.

Cancer Cell. 2017 Jun 12;31(6):820-832.e3. doi: 10.1016/j.ccell.2017.04.013. Epub 2017 May 18.

PMID:
28528867
9.

Characterizing the outcomes of metastatic papillary renal cell carcinoma.

Connor Wells J, Donskov F, Fraccon AP, Pasini F, Bjarnason GA, Beuselinck B, Knox JJ, Rha SY, Agarwal N, Bowman IA, Lee JL, Pal SK, Srinivas S, Scott Ernst D, Vaishampayan UN, Wood LA, Simpson R, De Velasco G, Choueiri TK, Heng DYC.

Cancer Med. 2017 May;6(5):902-909. doi: 10.1002/cam4.1048. Epub 2017 Apr 16.

10.

Comprehensive Analysis of Survival Outcomes in Non-Clear Cell Renal Cell Carcinoma Patients Treated in Clinical Trials.

de Velasco G, McKay RR, Lin X, Moreira RB, Simantov R, Choueiri TK.

Clin Genitourin Cancer. 2017 Mar 21. pii: S1558-7673(17)30066-6. doi: 10.1016/j.clgc.2017.03.004. [Epub ahead of print]

PMID:
28410911
11.

Complications After Metastasectomy for Renal Cell Carcinoma-A Population-based Assessment.

Meyer CP, Sun M, Karam JA, Leow JJ, de Velasco G, Pal SK, Chang SL, Trinh QD, Choueiri TK.

Eur Urol. 2017 Aug;72(2):171-174. doi: 10.1016/j.eururo.2017.03.005. Epub 2017 Mar 27.

PMID:
28359734
12.

Biosimilar biologic drugs: a new frontier in medical care.

Geynisman DM, De Velasco G, Sewell KL, Jacobs I.

Postgrad Med. 2017 May;129(4):460-470. doi: 10.1080/00325481.2017.1311196. Epub 2017 Apr 3. Review.

PMID:
28343424
13.

ICF-specific DNMT3B dysfunction interferes with intragenic regulation of mRNA transcription and alternative splicing.

Gatto S, Gagliardi M, Franzese M, Leppert S, Papa M, Cammisa M, Grillo G, Velasco G, Francastel C, Toubiana S, D'Esposito M, Angelini C, Matarazzo MR.

Nucleic Acids Res. 2017 Jun 2;45(10):5739-5756. doi: 10.1093/nar/gkx163.

14.

Electrochemical oxidation of cyanide on 3D Ti-RuO2 anode using a filter-press electrolyzer.

Pérez T, López RL, Nava JL, Lázaro I, Velasco G, Cruz R, Rodríguez I.

Chemosphere. 2017 Jun;177:1-6. doi: 10.1016/j.chemosphere.2017.02.136. Epub 2017 Feb 28.

PMID:
28279900
15.

Discontinuing VEGF-targeted Therapy for Progression Versus Toxicity Affects Outcomes of Second-line Therapies in Metastatic Renal Cell Carcinoma.

De Velasco G, Xie W, Donskov F, Albiges L, Beuselinck B, Srinivas S, Agarwal N, Lee JL, Brugarolas J, Wood LA, Rha SY, Kollmannsberger C, North S, Kanesvaran R, Rini BI, Broom R, Yamamoto H, Kaymakcalan MD, Heng DYC, Choueiri TK.

Clin Genitourin Cancer. 2017 Jun;15(3):403-410.e2. doi: 10.1016/j.clgc.2017.01.005. Epub 2017 Jan 12.

PMID:
28254206
16.

Erratum to: Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures.

Şenbabaoğlu Y, Gejman RS, Winer AG, Liu M, Van Allen EM, de Velasco G, Miao D, Ostrovnaya I, Drill E, Luna A, Weinhold N, Lee W, Manley BJ, Khalil DN, Kaffenberger SD, Chen Y, Danilova L, Voss MH, Coleman JA, Russo P, Reuter VE, Chan TA, Cheng EH, Scheinberg DA, Li MO, Choueiri TK, Hsieh JJ, Sander C, Hakimi AA.

Genome Biol. 2017 Mar 1;18(1):46. doi: 10.1186/s13059-017-1180-8. No abstract available.

17.

Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients.

De Velasco G, Je Y, Bossé D, Awad MM, Ott PA, Moreira RB, Schutz F, Bellmunt J, Sonpavde GP, Hodi FS, Choueiri TK.

Cancer Immunol Res. 2017 Apr;5(4):312-318. doi: 10.1158/2326-6066.CIR-16-0237. Epub 2017 Feb 28.

PMID:
28246107
18.

Molecular Subtypes Improve Prognostic Value of International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Model.

de Velasco G, Culhane AC, Fay AP, Hakimi AA, Voss MH, Tannir NM, Tamboli P, Appleman LJ, Bellmunt J, Kimryn Rathmell W, Albiges L, Hsieh JJ, Heng DY, Signoretti S, Choueiri TK.

Oncologist. 2017 Mar;22(3):286-292. doi: 10.1634/theoncologist.2016-0078. Epub 2017 Feb 20.

PMID:
28220024
19.

CENP-A chromatin disassembly in stressed and senescent murine cells.

Hédouin S, Grillo G, Ivkovic I, Velasco G, Francastel C.

Sci Rep. 2017 Feb 10;7:42520. doi: 10.1038/srep42520.

20.

Telomeres in ICF syndrome cells are vulnerable to DNA damage due to elevated DNA:RNA hybrids.

Sagie S, Toubiana S, Hartono SR, Katzir H, Tzur-Gilat A, Havazelet S, Francastel C, Velasco G, Chédin F, Selig S.

Nat Commun. 2017 Jan 24;8:14015. doi: 10.1038/ncomms14015.

Supplemental Content

Loading ...
Support Center